Patients' perception, and adherence to treatment with biosimilar adalimumab in psoriasis
- PMID: 34822212
- DOI: 10.1111/dth.15227
Patients' perception, and adherence to treatment with biosimilar adalimumab in psoriasis
References
REFERENCES
-
- Wu JJ, Valdecantos WC. Adalimumab in chronic plaque psoriasis: a clinical guide. J Drugs Dermatol. 2017;16:779-790.
-
- Jamshidi A, Gharibdoost F, Vojdanian M, et al. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis. Arthritis Res Ther. 2017;19:168.
-
- Wang W, Qiu Y, Zhao F, Zhang F. Poor medication adherence in patients with psoriasis and a successful intervention. J Dermatolog Treat. 2019;30:525-528.
-
- Hambraeus K, Tydén P, Lindahl B. Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: data from the SWEDEHEART registry. Eur J Prev Cardiol. 2016;23:340-348.
-
- Nguyen HL, Goldberg RJ, Gore JM, et al. Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry. Coron Artery Dis. 2010;21:336-344.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical